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Objectives. This study sought o evaluate the hemodynamic 
effects of intravenous sematilide hydrochloride, a selective class 
HI antiarrhythmic agent, in patients with heart failure and left 
ventricular systolic dysfunction. 
Background. Class I antiarrhythmie agents, which primarily 
slow conduction, can depress ventricular function, particularly in 
patients with heart failure. In contrast, pure class III agents, 
which selectively prolong repolarization, do not adversely affect 
hemodynamic variables in animal models, but there are no data 
evaluating their hemodynamic effects in humans. 
Methods. In 39 patients with congestive h art failure and a left 
ventricnlar ejection fraction <40%, hemodynamic and electrocar- 
diographic measurements were obtained at baseline, after a 
loading dose and during a maintenance infusion of intravenous 
sematilide using either a low (0.75 then 0.3 rag/rain) or high dose 
(1.5 then 0.6 rag/rain) regimen. The study had an 80% power to 
detect clinically meaningful differences in hemodynamic variables. 
Results. Both low (n = 20) and high (n = 19) dose sematilide 
infusions produced ose-dependent increases inQT interval (5 -+ 
8% [mean -+ SD] and 18 +- 10%, respectively) and corrected QT 
interval (4 _+ 8% and 14 _+ 10%), and high dose sematilide 
decreased heart rate by 7 "4" 10% (all p < 0.025 vs. baseline). 
Neither dose regimen had a statistically significant effect on any 
other hemodynamic variable, including mean arterial, right atrial, 
pulmonary artery and pulmonary capillary wedge pressures; 
cardiac index, stroke volume, systemic and pulmonary vascular 
resistances; and left ventricular stroke work index. Sematilide 
showed no adverse hemodynamic effects in patients with left 
ventricnlar ejection fraction _<25% or >25% and in patients with 
cardiac index <2 or ->2 liters/rain per m 2. Sustained polymorphic 
ventricular tachycardia (n = 1) and excessive QT prolongation 
(n = 4) were seen during the high dose. 
Conclusions. Sematilide, in the doses administered, prolonged 
repolarization but did not alter hemodynamic variables in pa- 
tients with heart failure. These data suggest that class III antiar- 
rhythmic agents, which selectively prolong repolarization, are not 
cardiodepressant bu may be proarrhythmic in humans, especially 
at high doses. 
(J Am Coil Cardiol 1995;26:1679-84) 
Currently available antiarrhythmic agents in clinical use in the 
United States have the propensity to depress myocardial 
contractility and reduce cardiac output (1-7). Because most 
patients with life-threatening ventricutar arrhythmias have 
poor left ventricular function, the negative inotropic effect of 
antiarrhythmic drugs limits their use in the population i which 
antiarrhythmic treatment is most often needed. Recently, ithas 
been suggested that class III antiarrhythmic agents, which 
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selectively block outward potassium currents and prolong 
repolarization, will have less adverse hemodynarnic effects than 
class I antiarrhythmic agents, which block sodium channels and 
slow conduction (1,8,9). Although investigations evaluating a
variety of new, pure class III antiarrhythmic agents in animal 
models have tended to support his hypothesis (9-17), the 
effects of these agents have not been evaluated inhumans with 
congestive heart failure. 
Sematilide hydrochloride, an analogue of procainamide, is 
a selective class III antiarrhythmic agent that blocks the 
delayed rectifier outward potassium current (10-13,18). It has 
no effects on sodium channels or on the autonomic nervous 
system and prolongs the ventricular effective refractory period 
and action potential duration in humans in a reverse use- 
dependent manner (12,13,18). Sematilide is undergoing clini- 
cal investigation and has been shown to be effective in prevent- 
ing the induction of sustained ventricular arrhythmias during 
electrophysiologic testing in humans (18,19). The objective of 
the present study was to evaluate the hemodynamic effects and 
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safety of two dosage regimens of intravenous sematilide hy- 
drochloride in patients with congestive heart failure and left 
ventricular systolic dysfunction. 
Methods 
Patients. Patients were considered for entry into this study 
if they had congestive heart failure of at least 2 months in 
duration (New York Heart Association functional classes II to 
IV) and a left ventricular ejection fraction <40%. Left ven- 
tricular ejection fraction was determined by radionuclide an- 
giography or two-dimensional echocardiography. The exclu- 
sion criteria were unstable angina, myocardial infarction within 
4 weeks, severe aortic stenosis, acute pulmonary edema or 
cardiogenic shock, constrictive pericarditis, restrictive car- 
diomyopathy, amyloid heart disease, long QT syndrome or 
baseline corrected QT interval (QTc) >450 ms, complete heart 
block, symptomatic bradycardia (heart rate <45 beats/min), 
symptomatic hypotension (systolic blood pressure <80 mm Hg), 
serum creatinine >2.4 mg/dl, amiodarone therapy within the 
previous 3months and known "allergic respon~ to procainamide 
or N-acetylprocainamide. 
Protocol. This was an open-label study of two dosage 
regimens of intravenous ematilide hydrochloride adminis- 
tered by loading and maintenance infusions and was conducted 
at five centers. The two dose levels selected have been used 
previously (unpublished ata) to measure the electrophysi- 
ologic response to sematilide in patients with sustained ven- 
tricular tachycardia. The protocol was prospectively designed 
to study two groups of patients. Twenty patients in functional 
class II or llI with a left ventricular ejection fraction between 
21% and 39% were classified as group A, and 19 patients in 
functional class III or IV with a left ventricular ejection 
fraction <30% were classified as group B. In group A, the 
initial l0 patients received low dose, then the subsequent 10 
patients received high dose, sematilide; in group B, 10 patients 
received low dose, then 9 patients received high dose, semati- 
lide. All patients received constant doses of digoxin, diuretic 
drugs and vasodilator agents, except hat patients in functional 
class II or III had their cardiovascular medications withheld on 
the morning of the study until the hemodynamic evaluations 
were completed. Patients in functional class IV were allowed 
to continue their cardiovascular medications. Antiarrhythmic 
drugs (class I and III) were discontinued at least 5 half-lives 
before the study. No cardioactive medications other than 
sematilide were administered during the hemodynamic study 
protocol. The protocol was approved by the institutional 
review boards at the five centers, and all patients gave written 
informed consent before participating in the study. 
After completion of the clinically indicated cardiac cathe- 
terization or electrophysiologic study, a right heart catheter- 
ization was performed. One patient had hemodynamic vari- 
ables measured and sematilide administered after angiographic 
dye used during coronary angiography and left ventriculography. 
All other patients were studied without preceding exposure to 
angiographic dyes. The following baseline measurements were 
made before administration f intravenous sematilide hydrochlo- 
ride in the fasting state and at least 15 min after placement of the 
right heart catheter: mean right atrial pressure, mean pulmonary 
artery pressure, pulmonary capillary wedge pressure, mean arte- 
rial pressure, heart rate, surface ECG intervals (PR, QRS, QT, 
QTc) and cardiac output. Mean arterial pressure (MAP) was 
derived from the systolic (SBP) and diastolic (DBP) blood 
pressures (MAP = DBP + (SBP - DBP)/3). The QTc interval 
was derived using the Bazett formula. Cardiac output was deter- 
mined by the thermodilution technique using the average of three 
consecutive measurements that did not vary by _+ 10% from one 
another. The following hemodynamic variables were calculated at 
baseline: cardiac index, stroke volume, stroke index, systemic 
vascular esistance index, pulmonary vascular esistance index 
and left ventricular stroke work index. After completion of 
baseline hemodynamic evaluations, the loading infusion (low 
dose 0.75 mg/min; high dose 1.5 mg/min) of intravenous semati- 
lide was administered over a 15-min period and was immediately 
followed by the maintenance infusion (low dose 0.3 mg/min; high 
dose 0.6 mg/min). The maintenance infusion of intravenous 
sematilide continued until completion of the hemodynamic eval- 
uations and did not exceed 75 min in duration. Hemodynamic 
and ECG evaluations, obtained in the same manner as the initial 
baseline measurements, were undertaken at the end of loading 
infusion and 30 min after the start of the maintenance infusion. 
Blood pressure and heart rate were determined atthe end of the 
loading infusion and at 15-rain intervals during the maintenance 
infusion. Blood samples for plasma sematilide concentrations 
were obtained before the administration f sematilide, atthe end 
of the loading infusion and once every 15 min during the 
maintenance infusion. 
Statistical analysis. Comparisons of baseline demograph- 
ics for low and high dose groups were made using the Student 
two-tailed t test at the alpha 0.05 level of significance. Hemo- 
dynamic and ECG measurements were analyzed using a 
repeated-measures analysis of variance model, including the 
effects of dose group (low, high), time (baseline, loading, 
maintenance) and the dose group-by-time interaction effect 
(p < 0.15) for a variable; then comparisons with baseline 
values were made separately for each dose group, using the 
within-patient estimate of variability to compare the mean 
change from baseline to zero at the alpha 0.025 level. The 
minimal detectable difference for comparisons with baseline 
values, within a dose group, was calculated using the within- 
patient estimate of variability for power 0.80 (alpha 0.025). 
Subgroup analyses were performed separately on the basis of 
baseline cardiac index (<2 vs. ->2 liters/min per m 2) and left 
ventricular ejection fraction (-<25% vs. >25%). Univariate 
linear regression analysis was used to investigate possible 
correlations between the plasma sematilide concentrations and 
the changes in QTc and RR intervals. A two-tailed t test was 
used to test he null hypothesis that the slope was equal to zero 
(i.e., no relation). Mean values _+ SD are reported. 
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Table 1. Effects of Low Dose Sematilide Infusion on 
Hemodynamic Variables 
Baseline Loading Maintenance 
HR (beats/min) 84 ± 18 83 ± 17 81 ± 18 
MAP (mm Hg) 96 ± 15 96 = 14 98 ± 16 
MRAP (mm Hg) 10 _+ 6 9 : 6 9 ± 5 
MPAP (ram Hg) 31 + 12 31 ± 11 31 ± 12 
PCWP (ram Hg) 20 ÷ 10 21 ± 10 20 + 9 
CI (liters/min per m-') 2.3 + 0.5 2.3 ± 0.6 2.3 ± 0.6 
SI (ml/m 2) 29 + 10 29 ± 10 30 : 10 
SVR1 (dynes.s.cm S/m-') 3,155 ± 966 3,242 + 902 3,401 = 1,182 
PVRI (dynes.s.cm 5/m:) 416 ± 221 373 + 160 355 - 160 
LVSWI (g.m/m 2) 32 + 15 32 + 15 35 + 14 
Data presented are mean value _+ SD. CI = cardiac index: HR - heart rate; 
Loading = 15 min after start of loading infusion; LVSWI = left ventricular 
stroke work index; Maintenance - 30 rain after start of maintenance infusion; 
MAP = mean arterial pressure: MRAP - mean right atrial pressure; MPAP - 
mean pulmonary artery pressure; PCWP - pulmonary capillary wedge pressure: 
PVRI = pulmonary vascular esistance index; S1 = stroke index; SVR[ = 
systemic vascular esistance index. 
Resu l ts  
Patient characteristics. Thirty-nine patients were enrolled 
in the study (38 men, 1 woman; mean [±SD] age 56 ± 11 years, 
range 37 to 74; mean left ventricular ejection fraction 24 ± 9%, 
range 8% to 38%; mean cardiac index 2.2 ± 0.5 liters/rain per 
m 2, range 1.2 to 3.5). Sixteen patients were in functional class 
II, 18 in class III and 5 in class IV. Twenty patients received a
low dose and 19 patients received a high dose of intravenous 
sematilide. There were no statistically significant differences in 
baseline demographic characteristics orhemodynamic indexes 
between the low and high dose sematilide groups with respect 
to age, weight, creatinine clearance, left ventricular ejection 
fraction or cardiac index. Twelve patients in the low and 11 in 
the high dosage group had a left ventricular ejection fraction 
-<25%; 8 patients in each dosage group had a left ventricular 
ejection fraction >25%. 
Hemodynamic evaluations. The effects of intravenous se- 
matilide on hemodynamic variables were evaluated separately 
for patients receiving the low and high dose regimens at the 
end of the loading infusion and 30 rain after the start of the 
maintenance infusion. The minimal detectable differences with 
80% power for each of the hemodynamic variables in the study 
were as follows: heart rate 4 beats/rain, mean arterial, right 
atrial, pulmonary artery and pulmonary capillary wedge pres- 
sures 3, 1, 3 and 2 mm Hg, respectively, cardiac index 0.2 
liters/min per m 2, stroke index 2 ml/m:, systemic and pulmo- 
nary vascular esistance indexes 326 and 105 dynes.s.cm-5/m 2, 
respectively, and left ventricular stroke work index 2 g.m/m ~. 
Thus, the study had sufficient power to detect clinically mean- 
ingful differences in hemodynamic variables. Low dose sema- 
tilide (20 patients) did not change heart rate significantly 
(Table 1), whereas high dose sematilide (19 patients) produced 
a small but statistically significant decrease in heart rate (Table 
2). Heart rate decreased by 7 ± 10% (p < 0.025 vs. baseline) 
during the maintenance infusion of high dose sematilide. 
Table 2. Effects of High Dose Sematilide Infusion on 
Hemodynamic Variables 
Baseline Loading Maintenance 
HR (beats/min) 87 _+ 19 78 _+ 13' 79 -+ 11' 
MAP (mm Hg) 93 + 13 94 _+ 16 96 +_ 20 
MRAP (mm Hg) 9 + 5 9 _+ 5 9 +_ 5 
MPAP (ram Hg) 30 + It  31 + 11 30 _+ 10 
PCWP (ram Hg) 20 _+ 9 19 + 8 20 +_ 8 
CI (liters/rain per m 2) 2.1 _+ 0.6 2.1 _+ 0.5 2.1 _+ 0.5 
SI (ml/m 2) 25 _ 8 26 _+ 7 27 _+ 7 
SVRI (dynes.s.cm 5/m2) 3,429 _+ 969 3,427 _+ 966 3,567 ± 1,170 
PVRI (dynes.s.cm ~/m 2) 420 _+ 229 476 +_ 264 398 _+ 241 
LVSWI (g.m/m 2) 26 _ 12 27 _+ 12 28 _+ 13 
*p < I).1105 versus baseline. Data presented are mean value -+ SD. Abbre- 
viations as in Table 1. 
Neither the low nor the high dosage regimen of intravenous 
sematilide had a statistically significant effect on any other 
hemodynamic variable (Tables 1 and 2). The hemodynamic 
effects of intravenous sematilide were also evaluated in pa- 
tients with a left ventricular ejection fraction -<25% (Fig. 1) 
versus >25% and in patients with a cardiac index <2 versus ->2 
liters/min per m 2. In each of these categories, sematilide 
showed no adverse hemodynamic effects at the low or high 
dose regimen. 
Electrophysiologic effects. The PR and ORS intervals were 
not significantly altered uring either the loading or mainte- 
nance infusions in patients receiving either the low or high 
dose regimen of intravenous sematilide (Table 3). The QT and 
OTc intervals increased significantly after the low dosage 
infusion of intravenous sematilide at 30 min after the start of 
the maintenance infusion. In patients receiving the high dosage 
infusion, QT and QTc intervals increased significantly at the 
end of the loading infusion and at all time points during the 
maintenance infusion. The QT interval increased by 5 ± 8% 
and 18 ± 10%, and the QTc interval increased by 4 ± 8% and 
14 ± 10% (all p < 0.025 vs. baseline) during low and high dose 
sematilide, respectively, at 30 rain after the start of the 
maintenance infusion. 
Pharmacokinetics. The plasma sematilide concentrations 
suggested linear disposition kinetics comparing the low and 
high dosage regimens during the loading (0.653 ± 0.496 and 
1.447 ± 1.667/zg/ml, respectively) and maintenance (0.612 -
0.501 and 1.111 ± 0.879/~g/ml, respectively) infusions. There 
were weak but statistically significant (p < 0.05) linear corre- 
lations between the plasma concentrations of sematilide and 
the changes in OTc intervals at the end of the loading infusion 
and at 15 (r = 0.38) and 30 min of the maintenance infusion. 
There were no statistically significant correlations between the 
plasma concentrations of sematilide and the changes in RR 
interval at any time point studied. 
Adverse effects. The two dosage regimens of sematilide 
were generally well tolerated. Adverse effects occurred in four 
patients who received high dose sematilide and were in func- 
tional class III. Four patients had excessive QT prolongation 
outside the limits defined in the protocol (QT > 515 ms or 
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Figure 1. Hemodynamic effects of 
high dose intravenous sematilide in 
11 patients with left ventricular 
ejection fraction <25%. Other 
than the decreases in heart rate 
(HR), there were no adverse he- 
modynamic effects. CI = cardiac 
index; MAP = mean arterial pres- 
sure; MRAP = mean right atrial 
pressure; PCWP = pulmonary cap- 
illary wedge pressure; SVRI = sys- 
temic vascular esistance index. 
Open columns = baseline; hatched 
columns = loading dose; solid col- 
umns = maintenance dose. Results 
shown are mean value (columns) -+ 
SD (vertical lines). *p < 0.05 ver- 
sus baseline. 
->25% increase from baseline). In one of these patients, who 
had no prior history of ventricular tachycardia, the QT prolon- 
gation was followed by spontaneous, hemodynamically desta- 
bilizing polymorphic ventricular tachycardia (torsade de 
pointes). This event occurred at the end of the maintenance 
infusion and required irect current cardioversion. No other 
adverse hemodynamic events occurred. 
Discuss ion  
Present study. The present study used invasive monitoring 
to evaluate the hemodynamic effects of an intravenous class III 
antiarrhythmic drug in patients with chronic congestive heart 
failure (functional c asses II to IV) and left ventricular systolic 
dysfunction (left ventricular ejection fraction <40%). Antiar- 
rhythmic drugs can depress myocardial contractility, reduce 
cardiac output and produce amarked eterioration in function 
when given to patients with congestive heart failure (2-6). 
Sematilide did not cause any acute adverse hemodynamic 
effects, even in the subset of patients with markedly depressed 
ventricular function (left ventricular ejection fraction <25% or 
cardiac index <2 liters/rain per m2). The doses administered 
produced clear electrophysiologic effects on ventricular repo- 
larization as evidenced by QTc interval prolongation. There 
was also a modest but significant decrease in heart rate at the 
higher dose. The findings of the present study may have 
important clinical implications. All currently available intrave- 
nous antiarrhythrnic drugs (lidocaine, procainamide and brety- 
lium) used for the acute termination or prevention of cardiac 
arrhythmias either markedly depress cardiac function or pro- 
duce hypotension. To our knowledge, the present study is the 
first to evaluate the hemodynamic effects of a pure class III 
antiarrhythmic agent in humans, particularly those with con- 
gestive heart failure. It confirms previous uggestions that the 
cardiodepressant effects of antiarrhythmic drugs in humans are 
related to sodium channel, calcium channel or beta-adrenergic 
blockade and are unrelated to selective ffects on repolariza- 
tion. 
Previous studies. The results of a number of recent clinical 
investigations (1-3,20) have emphasized that class I antiar- 
rhythmic agents, which slow conduction, can depress cardiac 
function and are potentially proarrhythmic. The combination 
of cardiodepression a d proarrhythmia may explain the failure 
of antiarrhythmic drugs to prevent sudden cardiac death and 
Table 3. Effects of Sematilide Infusion on Electrocardiographic Intervals 
Low Dose 
Baseline Loading Maintenance Baseline 
High Dose 
Loading Maintenance 
PR (ms) 189 _+ 35 184 _+ 40 184 _+ 44 174 _+ 24 179 _+ 27 175 _+ 28 
QRS (ms) 113_+37 114_+41 117_+41 100_+29 100_+29 103_+29 
QT (ms) 381 _+ 56 383 _+ 53 398 _+ 56* 356 _+ 44 375 _+ 46* 421 _+ 55* 
QT c (ms) 443 _+ 47 444 _+ 49 459 _+ 50* 424 _+ 29 441 _+ 41' 458 _+ 61' 
*p < 0.025 versus baseline. OTc = corrected QT interval; other abbreviations a in Table 1. 
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the finding that these agents may actually increase mortality in 
certain patient groups (21-26). Thus, class Ill antiarrhythmic 
agents have received increased interest and investigation, even 
though these agents have clearly been demonstrated to pro- 
duce proarrhythmic effects, in particular torsade de pointes 
(27). Amiodarone and sotalol appear to have high efficacy in 
suppressing ventricular tachyarrhythmias and potentially in 
decreasing mortality, but several studies (5-7) indicate that 
these agents can worsen congestive heart failure. However, 
neither of these agents is a pure class II1 agent because they 
exert a number of other clinically significant actions, including 
beta-adrenergic blockade. A recent study (18) demonstrated 
that sematilide, a selective class III agent, was effective in 
suppressing the induction of sustained ventricular tachycardia 
in 41% of patients treated with this agent. 
It has been suggested that a pure class III agent might have 
a positive inotropic effect that could be beneficial in the 
treatment of arrhythmias in patients with congestive heart 
failure. The mechanism of this effect is hypothesized to be 
secondary to prolongation of phase 3 of the action potential, 
which theoretically can increase intracellular calcium (28) 
without directly influencing peak calcium currents. In animal 
studies (9,29) the prolongation i  action potential duration 
produced by class III antiarrhythmic agents is associated with 
increases in contractile force. The hemodynamic effects of 
sematilide have been examined in conscious and anesthesized 
dogs with normal hearts or ischemia-induced heart failure (10). 
No significant deleterious effects on blood pressure, cardiac 
output, maximal rate of increase of left ventricular pressure 
(dP/dt) or coronary blood flow were demonstrated with intra- 
venous doses up to 100 mg/kg. Dofetilide, another class III 
antiarrhythmic agent, has also been used in investigations in 
both conscious and anesthetized dogs with normal or ischemic 
hearts or cardiac failure (14,15). In doses over a wide range, 
dofetilide produced either no significant change in cardiac 
function or small increases in left ventricular contractility. 
Studies with at least two other investigational c ass III agents 
have demonstrated similar findings in animal models (16,17). 
The results of the present study extend these observations to
humans with congestive heart failure. 
Electrophysioiogic effects. The electrocardiographic effects 
of sematilide, which included ecreases in heart rate and QTc 
prolongation without effect on PR or QRS intervals, are 
consistent with selective class III actions. The decrease inheart 
rate has been observed previously with sematilide and with 
other selective class III agents, such as d-sotalol (30), and is 
most likely a result of prolongation ofaction potential duration 
in the sinus node (31). In contrast o a previous tudy with 
sematilide (20), there were no statistically significant correla- 
tions between the plasma concentrations of sematilide and 
changes in RR intervals. As has been demonstrated with other 
agents that have the potential to produce torsade de pointes 
(32-34), the increases in QT and QTc intervals produced by 
sematilide were dose dependent and were linearly correlated 
with plasma sematilide concentrations. The combination of 
decreasing heart rate and prolonging repolarization may be 
particularly hazardous and raises concern regarding the poten- 
tial proarrhythmic effect of sematilide. Four (21%) of 19 
patients who received the high dose of sematilide had excessive 
QT prolongation. One of these patients developed spontane- 
ous, sustained, polymorphic ventricular tachycardia. This find- 
ing may limit the drug's usefulness at higher doses and is 
consistent with other eports of class III antiarrhythmic agents. 
Study limitations. 1) The present study was not designed 
as a blinded, placebo-controlled trial. However, the findings 
that sematilide did not alter hemodynamic variables and 
prolonged QT and QTc intervals in a dose-dependent manner 
make the need for a placebo control ess important. 2) The 
hemodynamic effects of antiarrhythmic drugs should be as- 
sessed after both short- and long-term oral therapy. A previous 
investigation (18) that evaluated the electrophysiologic actions 
of sematilide and included patients with depressed ventricular 
function found that no patient developed worsening or new 
symptoms of congestive heart failure during long-term oral 
sematilide therapy. 3) The decreases in heart rate may have 
offset any potentially positive inotropic effect of sematilide, 
and changes in autonomic tone may have obscured the direct 
effects of this agent on cardiac function. 
Conclusions. Intravenous sematilide, in the doses admin- 
istered, produced consistent class III antiarrhythmic effects on 
repolarization but exerted no adverse hemodynamic or car- 
diodepressant effects in patients with moderate to severe 
congestive heart failure. These results suggest hat selective 
class III antiarrhythmic drugs that block outward potassium 
channels and are devoid of sodium channel and autonomic 
effects may be used safely and will not adversely affect hemo- 
dynamic variables in patients with congestive heart failure. 
Concerns regarding the proarrhythmic potential of these 
agents econdary to excessive QT prolongation continue and 
may limit their clinical utility at higher doses. Larger studies 
with other intravenous and oral class III antiarrhythmic drugs 
designed to determine their long-term safety profile are war- 
ranted. 
We gratefully acknowledge th  assistance of the clinical cardiovascular research 
division of Berlex Laboratories n data collection and statistical analysis. 
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